C4 Therapeutics (CCCC) Non-Current Debt (2020 - 2023)

C4 Therapeutics' Non-Current Debt history runs 4 years deep, the most recent figure standing at $8.6 million for Q1 2023.

• In Q1 2023, Non-Current Debt fell 15.43% year-over-year to $8.6 million; the TTM figure through Mar 2023 stood at $8.6 million (down 15.43% YoY), while the FY2022 annual figure was $9.2 million, down 14.61% from the prior year.
• Non-Current Debt was $8.6 million for Q1 2023 at C4 Therapeutics, down from $9.2 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $10.8 million in Q4 2021 to a low of $8.6 million in Q1 2023.
• Historically, Non-Current Debt has averaged $9.9 million across 4 years, with a median of $10.2 million in 2022.
• The sharpest annual moves came in 2021 and 2023: Non-Current Debt grew 7.2% in 2021, then retreated 15.43% in 2023.
• A 4-year view of Non-Current Debt shows it stood at $10.1 million in 2020, then grew by 7.12% to $10.8 million in 2021, then fell by 14.61% to $9.2 million in 2022, then declined by 6.24% to $8.6 million in 2023.
• The last three Non-Current Debt figures came in at $8.6 million (Q1 2023), $9.2 million (Q4 2022), and $9.1 million (Q3 2022), per Business Quant data.